Pulmonx
San Jose, US · 1 known investors
Pulmonx develops the Zephyr Valve, a bronchoscopic medical device for treating severe COPD and emphysema without surgery. The device targets patients with severe lung disease requiring minimally invasive intervention.
HealthtechMedical Devices
Investors · 1
In the news
- Brokerages Set Pulmonx Corporation (NASDAQ:LUNG) PT at $5.58 - Defense Worlddefenseworld.net · 2026
- Pulmonx to Release Q2 2026 Financial Results July 29 | LUNG Stock Newsstocktitan.net · 2026
- Pulmonx Corporation Raises $66.0M | Signalbasetrysignalbase.com · 2026
- Pulmonx, Inc. Raises $32 Million for Launch of Emphysema Products - BioSpacebiospace.com · 2010
- Pulmonx News - Pulmonx Raises $32 Million for Launch of Emphysema Productspulmonx.com